Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type.

Abstract

24 patients with non-Hodgkin's lymphomas of low-grade malignancy (stage III and IV) were treated either with a single drug (prednimustine) or with combination chemotherapy (cyclophosphamide, vincristine and prednisone). Response to therapy was similar in both groups. Prednimustine induced complete remission in 6 from 13 patients, while in that group treated with combination chemotherapy a complete remission was recorded in 4 from 11 patients. Both regimens were well tolerated. Therapy with prednimustin has an advantage in oral administration enabling it to be used in out-patient practice.

• Authors: P Klener, J Háber
• Journal: Folia haematologica (Leipzig, Germany : 1928) (Folia Haematol Int Mag Klin Morphol Blutforsch) Vol. 112 Issue 1 Pg. 103-8 ( 1985) ISSN: 0323-4347 [Print] Germany
• PMID: 2581855 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Chlorambucil
• Vincristine
• Cyclophosphamide
• Prednimustine
• Prednisone

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chlorambucil (analogs & derivatives)
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Lymphoma (drug therapy)
• Male
• Middle Aged
• Prednimustine (therapeutic use)
• Prednisone (administration & dosage)
• Random Allocation
• Vincristine (administration & dosage)